Tuesday, February 3, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home AI & Quantum Computing

Oracle Shares Slump as Market Skepticism Overrides AI Partnership Denials

Felix Baarz by Felix Baarz
December 16, 2025
in AI & Quantum Computing, Earnings, Nasdaq, Tech & Software
0
Oracle Stock
0
SHARES
13
VIEWS
Share on FacebookShare on Twitter

Despite issuing firm denials regarding reported delays in its high-profile artificial intelligence infrastructure collaboration, Oracle Corporation saw its stock decline sharply on Monday. The shares closed down 2.7% at $184.79, extending a losing streak that has now erased approximately 15% of their value since the company’s disappointing quarterly earnings report last week. This persistent sell-off raises pressing questions among investors about the credibility of Oracle’s ambitious AI-driven growth narrative.

Earnings Report Sets the Stage for Concern

The current wave of investor apprehension was triggered by Oracle’s fiscal second-quarter results, released on December 10th. The figures presented a mixed picture:

  • Non-GAAP Earnings Per Share: $2.26, significantly surpassing estimates of $1.64.
  • Total Revenue: $16.06 billion, slightly missing the consensus forecast of $16.19 billion.
  • Cloud Revenue: $8.0 billion, representing a 34% year-over-year increase.

A standout figure was the record-breaking Remaining Performance Obligations (RPO), which surged 15% sequentially to $523 billion. While indicative of strong future demand, this massive backlog necessitates substantial upfront capital expenditure. Oracle subsequently announced a dramatic $15 billion increase in its capital investment plan for fiscal 2026, pushing the company’s total debt load above $100 billion. This aggressive spending commitment has directly pressured free cash flow and fueled market worries over potential margin erosion.

Partnership Rumors Meet Official Rebuttal

Adding to the negative sentiment, a Bloomberg report suggested that Oracle had pushed back the completion timeline for key data centers central to its multi-billion-dollar partnership with OpenAI from 2027 to 2028. This infrastructure is part of a broader collaboration reportedly valued at $300 billion.

Should investors sell immediately? Or is it worth buying Oracle?

Oracle moved to counter these claims on Monday afternoon. The company stated that all project milestones remain on schedule, emphasizing that site selection and delivery timelines were established jointly with OpenAI. It firmly denied any delays related to its contractual obligations.

The market’s reaction was unequivocal. Investors largely dismissed the clarification, with the stock trading a high volume of 43.6 million shares and closing near its daily low. The skepticism appears deeply rooted in concerns over the company’s escalating investment costs.

Analysts Recalibrate Expectations

In tandem with the stock’s decline, several equity research firms adjusted their outlooks. Analysts at Sanford C. Bernstein lowered their price target on Oracle from $364 to $339, while maintaining an “Outperform” rating. Similarly, KeyCorp reduced its target from $350 to $300, though it kept an “Overweight” recommendation. The consensus message from analysts is that while the long-term AI opportunity remains intact, near-term valuation models must account for the significantly higher expenditure profile.

A Critical Juncture for Investor Confidence

Oracle’s stock is currently testing a key support zone between $180 and $185. A decisive break below this level could signal further consolidation ahead. The immediate future hinges on Oracle’s ability to demonstrate tangible execution on its AI infrastructure plans, particularly the timelines associated with the OpenAI partnership. The company’s reiterated commitment is now under intense scrutiny. For Oracle, restoring market faith will require concrete delivery, not just promises.

Ad

Oracle Stock: Buy or Sell?! New Oracle Analysis from February 3 delivers the answer:

The latest Oracle figures speak for themselves: Urgent action needed for Oracle investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 3.

Oracle: Buy or sell? Read more here...

Tags: Oracle
Felix Baarz

Felix Baarz

My name is Felix Baarz, and I look back on over fifteen years of experience as a business journalist. I have always been fascinated by the mechanisms and dynamics of global financial markets as well as the complex economic and political interconnections that shape our world. With this passion, I have made a name for myself as an expert on international financial markets and dedicate myself with great commitment to making even the most complex topics understandable and accessible to my readers. My roots lie in Cologne, where I was born and raised. Early on, my curiosity about economic topics and international developments sparked my interest in journalism. After completing my studies, I began my career as a business editor at a respected German trade publication. Here I laid the foundation for my professional career, but my curiosity soon drew me out into the wider world. A turning point in my life was moving to New York, where I lived for six years and gained insight into leading media houses. In this vibrant metropolis, I was able to report firsthand from the heart of the global financial world. From daily developments on Wall Street to major economic policy decisions that make waves worldwide, I had the opportunity to write about central topics that move people and markets alike. This time shaped my perspective and sharpened my view of global interconnections.

Related Posts

QuantumScape Stock
Analysis

QuantumScape’s Pivotal Year: Scaling Up for Commercial Validation

February 3, 2026
CNO Stock
Analysis

CNO Financial Earnings Report: A Strategic Pivot Under the Microscope

February 3, 2026
Q2 Holdings Stock
Earnings

Q2 Holdings to Report Full-Year 2025 Financial Results

February 3, 2026
Next Post
NASDAQ 100 Stock

Tech Stocks Lead Market Decline as Bond Yields Climb

Walt Disney Stock

Disney Forges AI Alliance with OpenAI in Major Strategic Shift

Nvidia Stock

Nvidia's Strategic Pivot: Securing the AI Infrastructure Layer

Recommended

Biotechnology Trading online

Decline in Short Interest for Adobe NYSE ADBE Signals Bullish Sentiment

2 years ago
Cisco Stock

Cisco Stock Surges as Artificial Intelligence Drives Infrastructure Demand

3 months ago
Adaptive Biotechnologies Stock

Strategic Shift: Adaptive Biotechnologies Severs Major Pharma Alliance

6 months ago
Puma Stock

Puma Shares Face Critical Test Amid Mounting Challenges

4 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Q2 Holdings to Report Full-Year 2025 Financial Results

Merck KGaA’s Strategic Acquisition of SpringWorks Therapeutics Gains Momentum

Commerce Bancshares Surpasses Market Forecasts in Year-End Report

Strategic Moves at Genworth Financial Ahead of Earnings

BancFirst Strengthens Regional Footprint with Acquisition Finalization

iShares MAFE ETF Reaches Fresh 52-Week Peak

Trending

Acadia Stock
Analysis

Setback in Europe Clouds Growth Outlook for Acadia

by Robert Sasse
February 3, 2026
0

Acadia Pharmaceuticals has encountered a significant obstacle for its European expansion strategy. Market uncertainty followed the announcement...

QuantumScape Stock

QuantumScape’s Pivotal Year: Scaling Up for Commercial Validation

February 3, 2026
CNO Stock

CNO Financial Earnings Report: A Strategic Pivot Under the Microscope

February 3, 2026
Q2 Holdings Stock

Q2 Holdings to Report Full-Year 2025 Financial Results

February 3, 2026
SpringWorks Therapeutics Stock

Merck KGaA’s Strategic Acquisition of SpringWorks Therapeutics Gains Momentum

February 3, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Setback in Europe Clouds Growth Outlook for Acadia
  • QuantumScape’s Pivotal Year: Scaling Up for Commercial Validation
  • CNO Financial Earnings Report: A Strategic Pivot Under the Microscope

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com